11/16/2007 - Opexa Therapeutics' Amendment No.1 on Form 10-KSB/A Report Audit Includes "Going Concern" ...

11/05/2022 - Opexa Reports Third Quarter 2007 Financial Results

10/05/2022 - Opexa Therapeutics to Present at the BIO Investor Forum 2007

09/26/2007 - Opexa Therapeutics Appoints Dr. Dawn McGuire, Prominent Neurologist, to Multiple Sclerosis Clinical ...

09/20/2007 - Opexa Appoints Lorin J. Randall to Board of Directors

09/13/2007 - Opexa Therapeutics to Present at the First Annual Maxim Group Growth Conference

09/11/2021 - Opexa Therapeutics Gives Update on Phase IIb Trial of Tovaxin(R) for Treatment of Multiple Sclerosis

08/23/2007 - Opexa to Present Proprietary T-Cell Technology at Vaccine Conference on August 24, 2022

08/14/2007 - Opexa Reports Second Quarter 2007 Financial Results

08/08/2022 - Opexa Therapeutics Receives European Patent Notification for T-Cell Vaccine

06/27/2007 - Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice

06/21/2007 - Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin(TM) for ...

06/11/2021 - Opexa Presents Tovaxin(TM) Research at Federation of Clinical Immunology Societies Annual Meeting

05/22/2007 - Opexa Therapeutics Appoints Clinical Advisory Board to Support Diabetes Program

05/22/2007 - Opexa Therapeutics Appoints Dr. Mark Pittenger, to Scientific Advisory Board

05/17/2007 - Opexa Therapeutics Completes Patient Enrollment in Phase IIb Trial of Tovaxin(TM) for Treatment of ...

05/15/2007 - Opexa Reports First Quarter 2007 Results

05/07/2022 - Opexa Therapeutics to Present Progress on Development of Monocyte-Derived Pancreatic Islet Cells for ...

05/04/2022 - Opexa Therapeutics to Present at BIO 2007 Business Forum

04/03/2022 - Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin™ ...

03/19/2007 - Opexa Therapeutics to Be Featured in Live MN1.com Interview

03/19/2007 - Opexa Reports Year End 2006 Financial Results

02/16/2007 - Opexa Therapeutics to Present at the Roth Capital Partners 19th Annual OC Conference

02/14/2007 - Opexa Therapeutics Launches Tovaxin(TM) Clinical Trial Website for Multiple Sclerosis

02/06/2022 - Opexa Announces Encouraging Clinical Data on Novel T-Cell Vaccination Therapy for Rheumatoid Arthritis

01/30/2007 - Opexa Achieves Midpoint in Patient Admissions in Phase IIb Trial of Tovaxin(TM) for Multiple Sclerosis